BPC-157

Gastric pentadecapeptide derived from human gastric juice. Upregulates growth hormone receptors, promotes angiogenesis via VEGF, and modulates nitric oxide signaling. Accelerates tendon-to-bone healing and reverses systemic corticosteroid damage in multiple tissue types.

Half-life

2 hours

Bioavailability

Systemic via subcutaneous; local via intramuscular near injury site

Route

subcutaneous, intramuscular, oral

Evidence tier

T2 — Single-RCT or mechanistic

Optimization pillars

recovery

References

3 peer-reviewed

Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative

200–250 mcg/day

General recovery support

moderate

250–500 mcg/day

Active injury recovery

aggressive

500–750 mcg/day

Severe tissue damage

Monitoring

hs-crp
igf-1

Contraindications

active-cancer
pregnancy

References

PMID:21030672Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts — Growth Horm IGF Res, 2010
PMID:29898091Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract — Curr Pharm Des, 2018
PMID:33478356BPC 157 and its role in accelerating wound healing — Med Arch, 2021

Notes

BPC-157 is the recovery peptide with the widest tissue applicability. Tendons, ligaments, gut lining, muscle — the repair signal is not tissue-specific. The limitation is the evidence tier. Dozens of rodent studies, compelling mechanistic data, but no large-scale RCTs in humans. The anecdotal consistency is unusually strong for a T2 compound. The science will catch up or it will not. The rodent data is what you have to work with today.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See BPC-157 in a protocol matched to you